Neurocrine Biosciences
Amy Allan is an accomplished scientist with extensive experience in chemical development and CMC within the pharmaceutical industry. Currently serving as Principal Scientist at Neurocrine Biosciences since August 2020, Amy specializes in route optimization and kilogram scale-up to support preclinical and First In Human studies for CNS targets. Prior roles include Principal Scientist in Chemistry at Lundbeck La Jolla Research Center and Principal Scientist in Chemistry/CMC at Abide Therapeutics. Previous experience encompasses positions at Dart Neuroscience, Takeda San Diego, American Life Science Pharmaceuticals, ChemVentures Inc., and Attenuon, LLC, contributing to expertise in process and scale-up. Amy holds a PhD in Synthetic Organic Chemistry from UC Santa Barbara and a Bachelor of Science in Chemistry from California State University, Los Angeles.
This person is not in any teams
This person is not in any offices
Neurocrine Biosciences
7 followers
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.